Results 41 to 50 of about 118,257 (252)

Antiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014 [PDF]

, 2016
Resistance to antiretroviral agents is a significant concern in the clinical management of HIV-infected individuals, particularly in areas of the world where treatment options are limited.
Aghasadeghi, M.R., Baesi, K., Davarpanah, M.A., McFarland, W., Moradi, A., Naziri, H., Tabarraei, A.   +6 more
core   +1 more source

Detection of HIV-1 resistant to antiretroviral drugs among tomsk oblast population with newly diagnosed HIV-infection

Журнал инфектологии, 2020
The purpose of this paper is to evaluate the spreading of HIV-1 resistant to antiretroviral drugs among Tomsk Oblast population with newly diagnosed HIV-infection.Materials and methods.
D. P. Zyryanova, E. M. Astakhova, M. P. Gashnikova, T. N. Ismailova, E. F. Bocharov, A. S. Chernov, A. V. Totmenin, M. N. Gashnikova   +7 more
doaj   +1 more source

HIV‐1 establishes immediate latency in T cells expressing the viral Nef protein

FEBS Open Bio, EarlyView.
Nef is a viral protein often omitted from HIV‐1 reporter viruses. Consequently, its role in viral latency is unclear. We developed three novel dual reporter HIV‐1 derivatives that express Nef and allow for detection of latent and productive infection. Using these reporters, we show that Nef does not affect the establishment of immediate viral latency ...
Cindy Lam, Ivan Sadowski
wiley   +1 more source

Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site‐Specific Integration of CFTR and Mutation‐Agnostic Disease Rescue

Advanced Functional Materials, EarlyView.
Lipid nanoparticles (LNPs) are optimized to co‐deliver Cas9‐encoding messenger RNA (mRNA), a single guide RNA (sgRNA) targeting the endogenous cystic fibrosis transmembrane conductance regulator (CFTR) gene, and homologous linear double‐stranded donor DNA (ldsDNA) templates encoding CFTR.
Ruth A. Foley, Paul G. Ayoub, Vrishti Sinha, Colin Juett, Alicia Sanoyca, Emily C. Duggan, Lindsay E. Lathrop, Priyanka Bhatt, Kevin Coote, Beate Illek, Brigitte N. Gomperts, Donald B. Kohn, Steven J. Jonas   +12 more
wiley   +1 more source

Respiratory Failure Associated with the Lipodystrophy Syndrome in an HIV-Positive Patient with Compromised Lung Function

Canadian Respiratory Journal, 2001
Protease inhibitors, used as treatment in human immunodeficiency virus (HIV) infection, are associated with a syndrome of peripheral lipodystrophy, central adiposity, hyperlipidemia and insulin resistance. An HIV-positive patient with chronic obstructive
Natasha Press, Valentina Montessori, Tony R Bai, Julio Montaner   +3 more
doaj   +1 more source

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, EarlyView.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

Membrane Vesicles from Lacticaseibacillus Casei BL23 Exhibit Antimicrobial Activity Against Escherichia coli and Immunostimulatory Effects on Human Peripheral Blood Mononuclear Cells

Advanced Healthcare Materials, EarlyView.
Membrane vesicles derived from the probiotic Lacticaseibacillus casei BL23 demonstrate antimicrobial properties against Escherichia coli and a potential biological effect in improving the overall survival of C. elegans infected with Pseudomonas aeruginosa. These vesicles stimulated immune responses in primary cells without causing toxicity. Our results
Cecilia L. D'Antoni, Leila Pourtalebi Jahromi, Lorenzo Sana, Ana Paula Domínguez Rubio, Maja Dorfner, Jennifer Munkert, Heike Danzer, Philipp Arnold, Mikhail Lebedev, Esther Zanin, Oscar E. Pérez, Gregor Fuhrmann   +11 more
wiley   +1 more source

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat

Retrovirology, 2011
Background Maturation inhibitors are an experimental class of antiretrovirals that inhibit Human Immunodeficiency Virus (HIV) particle maturation, the structural rearrangement required to form infectious virus particles.
Konvalinka Jan, Maas Renée EM, Schipper Pauline J, Pokorná Jana, van Maarseveen Noortje M, Fun Axel, Nijhuis Monique   +6 more
doaj   +1 more source

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, EarlyView.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

Subtype-Specific HIV-1 Protease and the Role of Hinge and Flap Dynamics in Drug Resistance: A Subtype C Narrative

Viruses
The HIV-1 aspartic protease is an effective target for the treatment of HIV/AIDS. Current therapy utilizes a selection of nine protease inhibitors (PIs) in combination with other classes of antiretroviral drugs.
Dean Sherry, Zaahida Sheik Ismail, Tshele Mokhantso, Yasien Sayed   +3 more
doaj   +1 more source